Plasma P-Tau217: Detecting Alzheimer Disease with a Blood Test

Key Takeaways from AAIC 2025: Lifestyle Modifications, Biomarkers, Amyloid-Targeting Therapies, and More

Ana C. Pereira, MD, Associate Professor, Icahn School of Medicine at Mount Sinai, New York, NY, discusses key takeaways about the impact of patient lifestyle modifications on brain health, updates in biomarkers and disease-modifying therapies, and new frontiers in Alzheimer disease research based on research presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC). Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

The Brain Health Navigator: A Novel Program to Improve Alzheimer Disease Care

Gregory E. Cooper, MD, PhD, Director, Memory Center, Norton Neuroscience Institute, Louisville, KY, outlines the Brain Health Navigator program as a strategy to streamline dementia care pathways, ensuring earlier diagnosis and faster access to disease-modifying therapies. This program, developed by the Davos Alzheimer’s Collaborative, is designed to reduce system inefficiencies across primary and specialty care and improve access for all patients. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Beyond Slowing Cognitive Decline: Patient and Caregiver Perspectives on Alzheimer’s Treatment

This episode explores groundbreaking qualitative research from the University of Pennsylvania on patient and caregiver perspectives in Alzheimer disease. Dr. Katie Auriemma, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, and Dr. Carolyn Chow, Penn Medicine, Philadelphia, PA, discuss findings from interviews with patients and caregivers that reveal hopes, worries, and nuanced views on AD therapies—highlighting the importance of patient-centered outcomes, shared decision-making, and aligning treatment with family goals. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Beyond the Boardroom: Barbara Corcoran on Caregiving and Alzheimer Disease

In this episode, we are joined by entrepreneur and television personality, Barbara Corcoran. While many know Barbara for her business acumen and dynamic presence on Shark Tank, fewer may know the deeply personal and powerful story she shares today—her nine-year journey as a caregiver for her mother, who lived with Alzheimer disease. In this heartfelt conversation, Barbara opens up about the early signs her family overlooked, the emotional toll of watching her mother's personality shift, and the pivotal moment that changed their approach to caregiving. From practical strategies to navigate agitation in Alzheimer disease, to profound lessons in empathy, patience, and family dynamics, Barbara’s story offers inspiration and wisdom for caregivers and physicians. For more information, please visit www.RecognizeAlzheimersAgitation.com. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Plasma P-Tau217: Detecting Alzheimer Disease with a Blood Test

Sterling Johnson, PhD, Associate Director and Biomarker Core Leader in the Wisconsin Alzheimer’s Disease Research Center (ADRC), and a Clinical Neuropsychologist and Neuroscientist focused on understanding AD-related changes in the brain, details his research into the use of plasma p-tau217 as a blood-based biomarker for detecting Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]